

SEP 19 2005

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-571-273-8300 on Sept. 19, 2005

TOWNSEND and TOWNSEND and CREW LLP

By: Brenda J. Dolly
Brenda J. Dolly

AMENDMENT UNDER 37 CFR 1.116
EXPEDITED PROCEDURE -
EXAMINING GROUP 1645

PATENT

Attorney Docket No.: 015280-356100US
Client Ref. No.: E-201-1998/0-US-06

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

PASTAN et al.

Application No.: 09/673,707

Filed: January 11, 2001

For: RECOMBINANT IMMUNOTOXIN
DIRECTED AGAINST THE HIV-1
GP120 ENVELOPE GLYCOPROTEIN

Customer No.: 45115

Confirmation No. 3958

Examiner: Zeman, Robert A.

Technology Center/Art Unit: 1645

AMENDMENT UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1645

*D, not
enter 10/5/05*
Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Final Office Action mailed April 19, 2005 on the above-referenced application, please enter the following amendments and remarks:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 5 of this paper.

Remarks/Arguments begin on page 14 of this paper.